Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

In early 2026, Verdad Capital — a systematic investment firm led by Greg Obenshain, Daniel Rasmussen, and Anton Wintner, M.D. — published "Biotech Investing: Investment Approaches that Work in a Challenging Industry." It's the most rigorous public case we've seen for tracking specialist biotech fund holdings as an investment signal. The paper is the result of over a year of work. Verdad built their own database of biotech specialist holdings and company insider disclosures from SEC filings. They created a point-in-time dataset of more than 130,000 clinical trials. And they tested whether traditional quant factors (value, momentum, quality) work in biotech — or whether you need entirely different signals. Their starting point is sobering: of the ~1,000 biotechs that reached $200M+ market cap since 1996, 67% lost money. Roughly 50% were acquired at negative total returns, 10% delisted, and 40% are still public as "zombie biotechs" trading below cash. The median biotech delivered -15% annualized returns vs. +1% for the median US company.

Verdad's most striking finding is what happens when you sort biotech stocks by how heavily they are owned by specialist biotech funds. The data (September 2013 to October 2025) shows a clear monotonic relationship: - Quintile 1 (least specialist-owned): -2% annualized - Quintile 2: 5% - Quintile 3: 11% - Quintile 4: 15% - Quintile 5 (most specialist-owned): 20% annualized That's a 22-percentage-point spread from bottom to top quintile. Verdad frames specialist consensus as effectively a "quality" factor for biotech, analogous to how profitability metrics work in other sectors where companies actually have profits. The paper tells the story of Pharmacyclics to illustrate: in 2009, when the stock was $1.28 with only early BTK inhibitor data, specialists like OrbiMed, Quoque Capital, and Baker Brothers recognized its potential and began buying. A few years later, AbbVie acquired the company for $261.25 per share.

The most common objection to 13F-based strategies is the filing delay. Funds report holdings as of quarter-end, and filings are due 45 days later. By the time you see the data, it's stale. Verdad addresses this directly: specialist biotech funds typically hold positions for nearly two years, and the strongest signals come when multiple specialists own the same stock. Because of these long holding periods and the convergence effect, even with a two-month reporting lag, the 13F data remains "both robust and highly informative." One important nuance: 72% of specialist fund exposure is concentrated in large-cap biotech — because multi-billion-dollar funds can't invest exclusively in small caps. But specialists are best at identifying return opportunities in small stocks. In the smallest third of biotechs, the highest specialist concentration quintile delivered nearly 30% annualized returns vs. near-zero for stocks with no specialist concentration. The implication: smaller investors who can focus on smaller names have a structural advantage.

Verdad doesn't stop at fund holdings. They test two additional "expert" signals: Insider trades — When sorted by the strength of insider trade signals (filtered for high-information trades like buys vs. sales, reversals, clustering, and CFO purchases), the spread is significant: quintile 1 (most bearish insider signals) returned 0% annualized, while quintile 5 (most bullish) returned 20%. Short interest — Short sellers are especially good at identifying losers. The most-shorted biotech quintile returned -19% annualized, while the least-shorted returned 16%. Verdad notes that short sellers are "equally valuable to biotech specialist funds and company insiders" as guides. The paper argues that all three expert signals — specialist funds, insiders, and short sellers — illuminate different parts of the biotech landscape, and combining them produces a composite "quality" measure that works independently from value and momentum.

Verdad's findings map directly to what BiotechEdge does: - Specialist fund tracking — Verdad shows a 22-point return spread by specialist concentration. BiotechEdge tracks 15 specialist biotech funds through 13F filings, updated with every filing cycle. - Fund convergence — Verdad finds the strongest signals when multiple specialists own the same stock. Our convergence page surfaces exactly this. - Insider signal filtering — Verdad filters for high-information insider trades (buys, reversals, clustering, CFO transactions). BiotechEdge's AI noise filtering implements the same framework, separating routine 10b5-1 sales from conviction-driven purchases. The Verdad paper is the academic case. BiotechEdge is the daily implementation. In Part 2, we dig into the rest of the paper: why traditional quant factors (value and momentum) fail completely in biotech, how Verdad rebuilt them from scratch using clinical trial data, and the macro case for why biotech may be entering a new bull cycle.